Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05011305 · ClinicalTrials.gov registry record · Phase 2
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis
A Phase 2 study, sponsored by Zydus Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 189
- Enrollment target
NCT05011305 is a Phase 2 study that has completed, run by Zydus Therapeutics. The registered enrollment target is 189 participants.
The verdict
NCT05011305, a Phase 2 study, has completed, sponsored by Zydus Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 189 participants
- Enrollment target
Study Summary
Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis
Interventions
- DRUG Placebo
- DRUG Saroglitazar Magnesium 2 mg
- DRUG Saroglitazar Magnesium 4 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2021-08-18 |
| Est. Completion | 2025-09-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05011305
The ClinicalTrials.gov registry entry for NCT05011305 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zydus Therapeutics, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05011305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05011305 about?
NCT05011305 is a clinical study titled "Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis". Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis
What is the current status of trial NCT05011305?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 189 participants. The study started on 2021-08-18. Estimated completion is 2025-09-12.
What interventions are being tested in trial NCT05011305?
The interventions under investigation include: Placebo (DRUG), Saroglitazar Magnesium 2 mg (DRUG), Saroglitazar Magnesium 4 mg (DRUG).
Who is sponsoring clinical trial NCT05011305?
This trial is sponsored by Zydus Therapeutics, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.